uniQure N.V.

2 days ago · zacks.com

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.

5 days ago · globenewswire.com

~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~

18 days ago · seekingalpha.com

uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November 1. Three-year data met both FDA endpoints, showing 75% slowing of composite and 60% slowing of Total Functional Capacity.

20 days ago · newsfilecorp.com

New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

26 days ago · seekingalpha.com

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

1 month ago · schaeffersresearch.com

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?

1 month ago · globenewswire.com

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired uniQure securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.

1 month ago · zacks.com

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.

1 month ago · prnewswire.com

uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations.

1 month ago · seekingalpha.com

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing Transcript